

Respiratory disease in Austria



INTERNATIONAL
RESPIRATORY
COALITION

The International Respiratory Coalition (IRC) was founded to tackle one of global health's most overlooked challenges: the burden of respiratory disease.

We bring together national coalitions of health professionals, patient advocates and policymakers to develop and implement national respiratory health strategies that address prevention, treatment and care.


The ultimate goal is to reduce respiratory disease-related mortality by a third globally by 2030, in line with the UN Sustainable Development Goals.

The Austrian Respiratory Coalition joined the IRC in 2022 as a task force of the Austrian Society of Pneumology, representing an association of lung experts, patient organisations, health policy stakeholders and the pharmaceutical industry.

The central goals of the coalition are:

- Prevention of respiratory and lung diseases through the establishment of prevention programmes
- Reducing social inequalities and strengthening patients' rights
- Improving access to early diagnosis and best therapy
- Prioritising research on measures to promote lung health

Societal economic cost by disease:



**1.4
million**
people living with
respiratory
diseases

**10.5
thousand**
deaths from
respiratory
diseases

**246
thousand**
healthy life years
lost to respiratory
diseases

**€12.8
billion**
societal
economic cost
of respiratory
diseases

The IRC is made possible with the contributions of various stakeholders: IRC leadership is provided by the European Respiratory Society and European Lung Foundation; Additional stakeholders include: the IRC National Coalitions and the Global Allergy and Airways Patient Platform; Funding support is provided by AstraZeneca, Chiesi Group, GSK, MSD, Sanofi and Regeneron.

Data taken from IRC Lung Facts <https://international-respiratory-coalition.org/lung-facts/>

Published:
September 2026